chemotherapy

envie a um amigo share this

Patient-derived ovarian cancer explants: preserved viability and histopathologic

Ovarian carcinoma remains a major therapeutic challenge due to its tendency to develop resistance after initial response to chemotherapy. In this work, a collaboration between iBET, AbbVie and IPOLFG, we developed ovarian carcinoma patient-derived explant (OvC-PDE) cultures that retained architecture and cell type heterogeneity of the original tumour. This patient-derived model have potential applications in the study of drug response and resistance mechanisms and in the development of innovative precision medicine approaches.

Patient-derived ovarian cancer explants: preserved viability and histopathologic

Ovarian carcinoma remains a major therapeutic challenge due to its tendency to develop resistance after initial response to chemotherapy. In this work, a collaboration between iBET, AbbVie and IPOLFG, we developed ovarian carcinoma patient-derived explant (OvC-PDE) cultures that retained architecture and cell type heterogeneity of the original tumour. This patient-derived model have potential applications in the study of drug response and resistance mechanisms and in the development of innovative precision medicine approaches.

MiR-144 overexpression as a promising therapeutic strategy to overcome glioblastoma cell invasiveness and resistance to chemotherapy

Authors and Affiliations:

Cardoso AMS1,2, Sousa M1,3, Morais CM1,3, Oancea-Castillo LR4, Régnier-Vigouroux A4, Rebelo O5, Tão H6, Barbosa M6,7, Pedroso de Lima MC1, Jurado AS1,3.

1 Center for Neuroscience and Cell Biology, University of Coimbra, 3004-504 Coimbra, Portugal.

2 Institute for Interdisciplinary Research of the University of Coimbra, 3030-789 Coimbra, Portugal.

New mechanism behind Doxorubicin cardiotoxicity

A group of researchers from the Center for Neuroscience and Cell Biology (CNC) at the University of Coimbra (UC), uncovered a new mechanism behind the cardiotoxicity of the anticancer drug Doxorubicin (or Adriamycin) that can be explored in the future as a new therapeutic target to counteract the adverse effects of chemotherapy. Although Doxorubicin is a powerful chemotherapeutic agent, it has severe long-term adverse effects that compromise the cardiac function of patients.

Findings reveal a mitochondrial metabolic vulnerability that might be exploited to kill chemotherapy-resistant acute myeloid leukemia cells

Authors and Affiliations:

Sandrina Nóbrega-Pereira1, Francisco Caiado1, Tânia Carvalho1, Inês Matias1, Gonçalo Graça2, Luís Gafeira Gonçalves2, Bruno Silva-Santos1, Haakan Norell1 and Sérgio Dias1

1 Instituto de Medicina Molecular.
  • 2 Instituto de Tecnologia Quimica e Biológica.

 

Abstract:

CBMR researchers take a new step to help treat more aggressive brain tumors

Investigadores do CBMR dão novo passo para ajudar a tratar tumores cerebrais mais agressivos

Patrícia Madureira e a sua equipa de investigação acabam de publicar na revista Cells um artigo científico que pode ajudar a compreender o gliobastoma multiforme, um dos tumores cerebrais mais mortíferos.

Magnetic liposomes as nanocarriers for a new potential antitumor drug

A research team leaded by Elisabete Castanheira and Paulo Coutinho, of the Centre of Physics of University of Minho, has been focused on the development of magnetic liposomes (“magnetoliposomes”), which combine magnetic nanoparticles and liposomes. The developed systems have been tested as nanocarriers for new potential antitumor drugs. The latter have been obtained at the Centre of Chemistry of University of Minho (Maria João Queiroz’s research group). In this study, recently published, a new molecule especially active against breast cancer was tested.

Portuguese group combine nanoparticle delivery of gene therapy and standard chemotherapy to overcome leukemia

Specific gene silencing was vectorized via gold nanoparticles to enhance the killing potential of chemotherapy against leukemia cells. By targeting the fusion oncogene BCR-ABL1 using gold nanoaprticles in chronic myeloid leukemia cells, the Portuguese researchers were capable to enhance the therapeutic efficacy of standard chemotherapy in a combined strategy that this groups has been optimizing at UCIBIO (Research Unit on Applied Molecular Biosciences), Faculdade de Ciências e Tecnologia of Universidade Nova de Lisboa.

The Institute for Cancer Vaccines & Immunotherapy Third International Symposium on Immunotherapy

The Royal Society, London, United Kingdom

 

12 - 13 May, 2017

 

See more informations here: http://www.icvis.org.uk/